Filtered By:
Condition: Headache
Countries: Canada Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 24 results found since Jan 2013.
Girl, 27, mistook a stroke for an intense migraine
Carly White (left), 27, from Carmanville, Canada, thought she had a migraine on July 30. Her husband Nathanael (right) took her to the hospital the next day. He soon learned his wife had had a stroke.
Source: the Mail online | Health - September 19, 2017 Category: Consumer Health News Source Type: news
Canadian woman mistook a stroke for an intense migraine
Carly White (left), 27, from Carmanville, Canada, thought she had a migraine on July 30. Her husband Nathanael (right) took her to the hospital the next day. He soon learned his wife had had a stroke.
Source: the Mail online | Health - September 19, 2017 Category: Consumer Health News Source Type: news
Migraine with Aura as a Stroke Mimic.
PMID: 31657289 [PubMed - as supplied by publisher]
Source: The Canadian Journal of Neurological Sciences - October 27, 2019 Category: Neurology Authors: Park JJ, Kim SJ, Kim HY, Roh HG, Kim DW Tags: Can J Neurol Sci Source Type: research
An Important Pediatric Stroke Mimic: Hemiplegic Migraine.
PMID: 31918771 [PubMed - as supplied by publisher]
Source: The Canadian Journal of Neurological Sciences - January 9, 2020 Category: Neurology Authors: Jurkiewicz MT, Vossough A, Pollock AN Tags: Can J Neurol Sci Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
1. Abstract Title: Management of Cerebral Vein Thrombosis in a Large Canadian Tertiary Hospital
Introduction: Cerebral vein thrombosis (CVT) is an uncommon cause of stroke and is more likely to affect young adults and children. Women have a three-fold increased risk compared to men, owing to gender specific factors such as oral contraceptive use (OCP), pregnancy, and hormone replacement therapies. The presenting symptoms of CVT are non-specific and include headache, seizure, focal neurological deficits, or coma as the most severe presentation. The rarity and variable symptoms of the disease leads to delayed diagnosis and implementation of treatment.
Source: Thrombosis Research - October 1, 2018 Category: Hematology Authors: Lana Castellucci, Philip Chiang Source Type: research
Management of Cerebral Vein Thrombosis in a Canadian Tertiary Hospital
Introduction: Cerebral vein thrombosis (CVT) is an uncommon cause of stroke and is more likely to affect young adults and children. Women have a three-fold increased risk compared to men, owing to gender specific factors such as oral contraceptive use (OCP), pregnancy, and hormone replacement therapies. The presenting symptoms of CVT are non-specific and include headache, seizure, focal neurological deficits, or coma as the most severe presentation. The rarity and variable symptoms of the disease leads to delayed diagnosis and implementation of treatment. With improved imaging techniques and increased awareness in recent y...
Source: Blood - November 21, 2018 Category: Hematology Authors: Castellucci, L. A., Chiang, P. Tags: 332. Antithrombotic Therapy: Poster II Source Type: research
Clinical characteristics and outcomes of patients with takotsubo syndrome versus spontaneous coronary artery dissection
CONCLUSIONS: These findings suggest that women are at higher risk for TTS and SCAD compared to men, which should be considered in the differential diagnosis of those presenting with acute coronary syndrome. Additionally, emotional stressors play a significant role in triggering events particularly in younger women suffering from SCAD. The present findings may help clinicians better differentiate these 2 entities and aid in the appropriate risk stratification, diagnosis, and management.TRIAL REGISTRATION: ClinicalTrials.gov no. NCT01947621.PMID:34165180 | DOI:10.5603/CJ.a2021.0065
Source: Cardiology Journal - June 24, 2021 Category: Cardiology Authors: Victoria L Cammann Annahita Sarcon Konrad A Szawan Michael W ürdinger Saif Azam Jerold Shinbane Burkhardt Seifert Jelena R Ghadri Jacqueline Saw Christian Templin Source Type: research
